Identification and immunotherapeutic targeting of antigens induced by chemotherapy

Nat Biotechnol. 2006 Feb;24(2):205-9. doi: 10.1038/nbt1185. Epub 2006 Jan 29.


Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xenografts in mice treated with CPT-11, whereas either agent alone was less effective. These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • Antineoplastic Agents / administration & dosage
  • Base Sequence
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Camptothecin / immunology
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / immunology*
  • Cell Line, Tumor
  • Drug Delivery Systems / methods*
  • Female
  • Humans
  • Immunotherapy / methods*
  • Irinotecan
  • Membrane Proteins / immunology
  • Mice
  • Mice, Nude
  • Molecular Sequence Data
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Membrane Proteins
  • Irinotecan
  • Camptothecin

Associated data

  • GENBANK/U58516